Quinic acid attenuates arsenic-induced hepatic injury and hyperglycemia in mice via GLUT2 upregulation and suppression of oxidative stress and inflammation Authors: Seyedeh Diba Aghamirzadeh, Mohammad Javad Khodayar, Mehrnoush Matin, Annahita Rezaie, Mehrnoosh Moosavi Published: 2025 ABSTRACT AbstractChronic exposure to arsenic is associated with an increased risk of developing diabetes mellitus. Quinic acid (QA), a cyclic polyol compound with known antioxidant and anti-inflammatory properties, was evaluated for its protective effects against sodium arsenite (SA)-induced hyperglycemia and hepatotoxicity in mice. In this study, mice were divided into 6 groups: control, SA (10 mg/kg), QA (200 mg/kg), and three groups receiving SA + QA at doses of 50, 100, or 200 mg/kg. After 28 days of treatment, fasting blood glucose was measured, followed by a glucose tolerance test. On day 30, blood samples were collected for analysis of serum liver enzymes, triglycerides, and cholesterol. Hepatic oxidative stress markers, inflammatory markers, glucagon-like peptide-1 levels, and serum levels of gastric inhibitory polypeptide and insulin were also measured. Hepatic glucose transporter protein 2 (GLUT2) expression was assessed by Western blot. Histological analysis of liver and pancreatic tissues was also performed. Arsenic exposure resulted in impaired glucose tolerance, oxidative stress, inflammation, and liver injury. Treatment with QA significantly reduced these effects, restored antioxidant defenses, reduced inflammatory responses, and improved glycemic control. Western blot analysis showed that GLUT2 protein expression was decreased in the SA group, whereas QA increased hepatic GLUT2 expression in a dose-dependent manner.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-33451-3.Keywords: Quinic acid, Hepatotoxicity, Mice, Arsenic, Diabetes, GLUT2Subject terms: Biochemistry, Diseases, Gastroenterology, Physiology Introduction Arsenic is a toxic metalloid found naturally in the environment and poses a major threat to both ecological systems and human health. It is commonly detected in various environmental media, including water, food, soil, and air1. Contamination arises from both natural geological processes and human activities, contributing to its widespread global distribution2. The World Health Organization (WHO) has established a maximum allowable concentration of 10 parts per billion (ppb) for arsenic in drinking water; however, contaminated water remains the primary source of exposure in many communities1. Inorganic arsenic exists primarily in trivalent (As + 3) and pentavalent (As + 5) forms, with the trivalent form being significantly more toxic3. Chronic arsenic exposure is associated with impaired glucose tolerance and an increased risk of diabetes mellitus4,5. Arsenic exposure has been reported to disrupt glucose regulation in experimental models and lead to the development of insulin resistance and related metabolic disorders6. The mechanisms by which arsenic induces metabolic dysfunction include the disruption of key glucose-regulating pathways. Incretins, such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), are gut-derived hormones that enhance insulin secretion and are essential for postprandial glucose regulation7,8. Glucose transporter 2 (GLUT2), a key hepatic and pancreatic glucose transporter, facilitates glucose uptake and is essential for maintaining glucose homeostasis. Downregulation of GLUT2 by arsenic impairs glucose sensing and transport, further contributing to hyperglycemia9. Standard chelators like dimercaptosuccinic acid (DMSA) and dimercaprol are commonly used to remove heavy metals, but do not directly mitigate oxidative stress or restore disrupted metabolic pathways10. Instead, we selected quinic acid (QA), a cyclic polyol compound (C₇H₁₂O₆) found in coffee, blueberries, plums, kiwis, and other medicinal plants11,12. Quinic acid exhibits several pharmacological properties relevant to metabolic disorders, including antioxidant, anti-inflammatory, and antidiabetic effects13–16. It enhances antioxidant enzyme activity and neutralizes free radicals, mitigating redox imbalance in cells17. QA exhibits beneficial effects on glycemic control. Recent evidence shows that QA is a potent α-glucosidase inhibitor, outperforming citric, malic, and gallic acids. Furthermore, QA significantly reduced the formation of advanced glycation end products (AGEs) and fructosamine, and attenuated glucose absorption in Caco-2 intestinal epithelial cell18. Additionally, in a combined treatment with quercetin, QA helped normalize elevated blood glucose in diabetic rats, although neither compound affected glycemic status in normal animals13. Although QA is known for its antioxidant and antidiabetic properties, its role in protecting against arsenic-induced hepatic injury and glucose dysregulation via GLUT2 modulation is novel and constitutes the key contribution of this study. In this regard, the study was designed to investigate the possible therapeutic efficacy of QA as a potent antioxidant and an anti-inflammatory agent against SA hyperglycemia and hepatotoxicity in a mouse model. Results QA effect of fasting blood sugar (FBS) and glucose tolerance test (GTT) Mice exposed to SA exhibited significantly elevated blood glucose levels compared to controls. However, treatment with QA (100 mg/kg and 200 mg/kg) significantly improved fasting hyperglycemia and glucose intolerance (Fig. 1A–C), as shown by decreased blood glucose levels and area under the curve (AUC) during GTT. QA alone has no side effects and does not significantly alter the measured parameters in control mice, which strengthens the safety of this compound. Effects of quinic acid (QA) on blood sugar levels in sodium arsenite (SA)-induced glucose intolerance in mice. (A) Fasting blood sugar (FBS). (B) Glucose tolerance test (GTT). (C) Area under the curve (AUC) (mg min/dl) during the GTT. The results are presented as mean ± SEM (n = 8). *Significant difference with the control group (***P < 0.001). #Significant difference with the SA group (#P < 0.05, ##P < 0.01). QA effect on serum liver function enzymes Serum levels of aminotransferase (AST), alanine aminotransferase (ALT) and, alkaline phosphatase (ALP) were significantly elevated in the SA group (P < 0.001), indicating hepatocellular injury. QA administration before arsenic exposure significantly reduced these enzyme levels, particularly at 100 and 200 mg/kg doses (Fig. 2A–C). Effects of quinic acid (QA) on liver function enzymes of serum in sodium arsenite (SA)-induced hepatotoxicity in mice. (A) Alanine aminotransferase (ALT). (B) Aspartate aminotransferase (AST). (C) Alkaline phosphatase (ALP).The results are presented as mean ± SEM (n = 8). *Significant difference with the control group (**P < 0.01 and ***P < 0.001). #Significant difference with the SA group(#P < 0.05, ##P < 0.01 and ###P < 0.001). QA effect on hepatic lipid profile alterations Arsenic exposure resulted in a marked increase in triglyceride (TG) and total cholesterol levels (Fig. 3A–B). QA treatment considerably reversed these lipid abnormalities, especially at 100 and 200 mg/kg doses. Effects of quinic acid (QA) on serum lipid profiles in sodium arsenite (SA)-induced hepatotoxicity in mice. (A) Triglyceride (TG). (B) Total cholesterol (TC). The results are presented as mean ± SEM (n = 8). * Significant difference with the control group (***P < 0.001). # Significant difference with the SA group (#P < 0.05, ## P < 0.01 and ###P < 0.001). QA effect on hepatic oxidative stress markers and nitric oxide (NO) levels The SA group showed a significant reduction in antioxidant enzymes, including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), as well as a decrease in total thiol content, accompanied by elevated TBARS and NO levels (Fig. 4A–F). QA (100 mg/kg and 200 mg/kg) significantly restored antioxidant capacity, as evidenced by increased SOD, CAT, and GPx levels, as well as reduced TBARS and NO concentrations. Effects of quinic acid (QA) on hepatic redox biomarkers in sodium arsenite (SA)-induced hepatotoxicity in mice. (A) Superoxide dismutase (SOD). (B) Catalase (CAT). (C) Glutathione peroxidase (GPx). (D) Total thiol content. (E) Thiobarbituric acid reactive substances (TBARS). (F) Nitric oxide (NO). The results are presented as mean ± SEM (n = 8). *Significant difference with the control group (***P < 0.001). #Significant difference with the SA group (#P < 0.05, ##P < 0.01 and ### P < 0.001). QA effect on gastric inhibitory polypeptide (GIP) and insulin Figure 5 shows the levels of GIP and insulin (Fig. 5A, B). In the group that received SA alone, the level of both GIP and insulin decreased significantly compared to the control group (P < 0.001). The levels of these factors increased in the group that received QA simultaneously with SA, and this increase was significant in the group that received QA at a dose of 200 mg/kg for both GIP (P = 0.04) and insulin (P < 0.01) when compared to the SA group. Effect of quinic acid (QA) on serum GIP and insulin levels in sodium arsenite (SA)-induced hepatotoxicity in mice. (A) Gastric inhibitory polypeptide (GIP). (B) Insulin. The results are presented as mean ± SEM (n = 8).*Significant difference with the control group (**P < 0.01 and ***P < 0.001). #Significant difference with the SA group (#P < 0.05 and ##P < 0.01). QA effect on hepatic inflammatory factor As illustrated in Fig. 6, tumor necrosis factor-alpha (TNF-α) levels were significantly elevated in the SA-treated group compared to controls (P < 0.001), while QA (100 mg/kg and 200 mg/kg) administration markedly suppressed TNF-α levels. Effect of quinic acid (QA) on tumor necrosis factor alpha (TNF-α) in sodium arsenite (SA)-induced hepatotoxicity in mice. The results are presented as mean ± SEM. *Significant difference with the control group (***P < 0.001). #Significant difference with the SA group (#P < 0.05 and ## P < 0.01). QA effect on liver protein expression of GLUT2 and GLP-1 As shown in Fig. 7, Western blot analysis revealed that GLUT2 protein expression was significantly reduced in the SA group compared to the control group (P < 0.001). However, administration of QA at doses of 100 and 200 mg/kg substantially upregulated hepatic GLUT2 expression (Fig. 7B). Similarly, hepatic GLP-1 levels were significantly reduced in the SA group but were restored by QA 200 mg/kg treatment (Fig. 7C). Effects of quinic acid on hepatic GLUT2 protein expression and GLP-1 levels in sodium arsenite (SA)-induced hepatotoxicity. (A) Hepatic GLUT2 protein expression. (B) Representative Western blot analysis of liver tissues for GLUT2 and GAPDH. (C) Hepatic GLP-1 levels. GLUT2 protein levels were quantified relative to the loading control GAPDH. The results are presented as mean ± SEM. *Significant difference with the control group (***P < 0.001). #Significant difference with the SA group (# P < 0.05, ##P < 0.01). QA effect on histopathological changes in liver and pancreas Histopathological examination of the liver Microscopic examination of liver sections from the SA group showed multiple large foci of hepatocyte necrosis accompanied by hemorrhage (Fig. 8C). Hepatocyte necrosis was identified by increased cytoplasmic eosinophilia, along with pyknosis, karyolysis, and karyorrhexis. Treatment with QA at 50 and 100 mg/kg resulted in a dose-dependent reduction in the size and number of necrotic foci and hemorrhage (Fig. 8D, E). In the SA + QA 200 mg/kg group, no foci of hemorrhage were observed, and the number of necrotic hepatocytes was significantly reduced, with the liver structure closely resembling the normal control group (Fig. 8A, B, F). Histological scoring was performed based on a semi-quantitative scale (0–3) for necrosis and hemorrhage (Table 1A). Liver histopathology (H&E staining; scale bars: 100 μm, 20 μm). Control (A) and QA (200 mg/kg) (B) show normal liver. SA (C) induces hepatocyte necrosis (↑ eosinophilia, nuclear changes—pyknosis, karyolysis, karyorrhexis; arrows) and hemorrhage (stars). SA + QA50 (D) shows similar necrosis and hemorrhage. SA + QA100 (E) exhibits reduced necrosis and hemorrhage. SA + QA200 (F) restores normal liver structure. Table 1Histopathological scoring of liver in experimental groups (A).AGroupsLiver necrosis (0–3)Hemorrhage (0–3)Control0.0 ± 0.00.0 ± 0.0QA (200 mg/kg)0.0 ± 0.00.0 ± 0.0SA2.8 ± 0.4***2.6 ± 0.5***SA + QA (50 mg/kg)2.0 ± 0.61.8 ± 0.4SA + QA (100 mg/kg)1.4 ± 0.5##1.2 ± 0.4##SA + QA (200 mg/kg)0.4 ± 0.5###0.0 ± 0.0###BGroupsIslet diameter (µm)Control107.0 ± 7.5QA (200 mg/kg)105.0 ± 8.8SA70.8 ± 5.4***SA+QA (50 mg/kg)73.0 ± 4.1SA+QA (100 mg/kg)78.3 ± 3.9SA+QA (200 mg/kg)91.8 ± 5.3##Scoring: 0 = normal, 1 = mild, 2 = moderate, 3 = severe. Diameters of the Langerhans Islets measured using motic software (B).***p < 0.001, ∗∗P < 0.01 vs. control; ##p < 0.01, ###p < 0.001 vs. SA group. Histopathological scoring of liver in experimental groups (A). Scoring: 0 = normal, 1 = mild, 2 = moderate, 3 = severe. Diameters of the Langerhans Islets measured using motic software (B). ***p < 0.001, ∗∗P < 0.01 vs. control; ##p < 0.01, ###p < 0.001 vs. SA group. Histopathological examination of the pancreas In the control and QA-only groups, the pancreas displayed a normal structure with multiple large islets of Langerhans (Fig. 9A, B). In contrast, the SA group showed a significant reduction in both the number and size of the islets of Langerhans, indicating cell death within the islets (Fig. 9C, Table 1B). The SA + QA 50 and 100 mg/kg groups showed some islets with reduced size (Fig. 9D, E). However, the SA + QA 200 mg/kg group showed a marked increase in both the number and size of the islets, restoring the morphology close to that of the control group (Fig. 9F). Pancreatic histopathology ((H&E staining; scale bars: 100 μm, 20 μm). Control (A) and QA (200 mg/kg). (B) show normal architecture with large islets of Langerhans (stars). SA (C) markedly reduces islet number and size. SA + QA50 (D) shows a similar reduction. SA + QA100 (E) exhibits slight islet size recovery. SA + QA200 (F) restores islet number and size to near-control levels. Discussion Arsenic is a widespread environmental pollutant that poses serious risks to human health. Chronic exposure—primarily through contaminated drinking water and food—leads to accumulation in the liver, the main organ responsible for metabolism and detoxification. This makes the liver especially vulnerable to arsenic-induced injury. Epidemiological and experimental studies increasingly link arsenic exposure to metabolic disturbances, including hyperglycemia and type 2 diabetes5,19,20. In our study, SA exposure in mice induced significant hyperglycemia, glucose intolerance, liver damage, oxidative stress, and inflammation—findings consistent with this growing body of evidence. At the cellular level, inorganic arsenic disrupts mitochondrial function by inhibiting enzymes involved in oxidative phosphorylation and ATP synthesis21. Trivalent arsenic has a high affinity for sulfhydryl groups on key metabolic enzymes involved in glucose metabolism and cellular signaling, such as pyruvate dehydrogenase and α-ketoglutarate dehydrogenase. Inhibition of these enzymes disrupts mitochondrial ATP production and triggers oxidative stress, ultimately leading to pancreatic β-cell dysfunction and apoptosis. The pancreas, with its high metabolic activity and limited antioxidant defenses, is particularly vulnerable to these effects22,23 . . We observed a marked reduction in both the number and size of pancreatic islets of Langerhans in the SA group, supporting the notion that arsenic causes β-cell toxicity and impairs insulin secretion. The liver, a central extrapancreatic organ in regulating metabolic processes, is critically involved in glucose and lipid metabolism, including their synthesis, utilization, and storage. Therefore, liver dysfunction plays a pivotal role in the development of diabetes24. In our model, SA exposure significantly elevated serum ALT, AST, and ALP—biochemical markers of hepatocellular injury. Histopathological analysis further confirmed liver damage. Given the liver’s key role in glucose and lipid metabolism, this dysfunction likely contributes to the observed hyperglycemia and dyslipidemia (elevated triglycerides and cholesterol). A central mechanism of arsenic toxicity is oxidative stress. We found that SA exposure markedly reduced the activity of antioxidant enzymes—SOD, CAT, and GPx—and depleted total thiol content. Concurrently, lipid peroxidation (as measured by TBARS) and nitric oxide (NO) levels were significantly elevated. These findings align with prior reports linking redox imbalance to arsenic-induced hepatic and metabolic injury25–28. Notably, QA treatment dose-dependently reversed these changes. QA restored antioxidant enzyme activities and reduced TBARS and NO levels. As a cyclic polyol rich in hydroxyl groups, QA likely acts both as a direct free radical scavenger and as an inducer of endogenous antioxidant defenses16,29. This dual action may offer advantages over conventional chelators by targeting both the toxicant and its downstream oxidative consequences. In addition to oxidative stress, chronic inflammation contributed to arsenic’s pathogenic effects. The SA group showed significantly elevated TNF-α levels—a pro-inflammatory cytokine known to promote insulin resistance and β-cell dysfunction30. QA treatment suppressed TNF-α and NO production in a dose-dependent manner, suggesting potent anti-inflammatory activity. This effect is consistent with studies on other natural compounds that mitigate metabolic inflammation31. Our mechanistic insights also involve key regulators of glucose homeostasis. Western blot analysis revealed that SA exposure significantly downregulated hepatic GLUT2 protein expression. GLUT2 is essential for glucose sensing and transport in the liver and pancreatic β-cells32. Its suppression likely exacerbates hyperglycemia. These findings suggest that QA’s antidiabetic effects may be partially attributable to the reversal of arsenic-induced downregulation of hepatic GLUT2. Although GLP-1 was assayed in liver tissue homogenates in this study, it is important to note that GLP-1 is not synthesized in the liver. It is primarily secreted by intestinal L-cells and rapidly degraded in circulation, with the liver contributing to its clearance rather than its production33. It enhances glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes β-cell survival—making it a key regulator of glucose homeostasis34. Consequently, GLP-1 detected in liver homogenates likely reflects trapped circulating hormone or degradation intermediates, and its concentration in this compartment does not reflect biologically active or secreted GLP-1 levels. Future studies should assess plasma (or serum) GLP-1, preferably the intact, active form, to draw valid conclusions about incretin status. The observed metabolic improvements with QA treatment may still involve GLP-1–mediated pathways, but this would need to be confirmed using appropriate systemic measurements. In summary, our data indicate that QA exerts protective effects against arsenic-induced metabolic and hepatic toxicity through multiple interconnected pathways: (1) attenuation of oxidative stress via enhanced antioxidant defense, (2) suppression of inflammation by reducing TNF-α and NO, and (3) improvement of glucose homeostasis through preservation of islet morphology, upregulation of hepatic GLUT2, and restoration of GLP-1. While these findings are promising, it is important to note that this study was conducted in a murine model (Fig. 10). Therefore, the therapeutic potential of QA in humans remains to be established. Further research, including pharmacokinetic and safety studies, is needed before clinical translation can be considered. Nonetheless, QA may represent a natural candidate for mitigating metabolic disturbances associated with environmental arsenic exposure. Graphical representation of the proposed protective mechanism of quinic acid against arsenic-induced hepatotoxicity and glucose intolerance. Quinic acid (QA) reduces fasting blood sugar and improves glucose intolerance. Its mechanism involves enhancing the cellular antioxidant defense system, reducing inflammation, and upregulating GLP-1 and GLUT2.Portions of the graphical abstract were drawn using images from Servier Medical Art(https://smart.servier.com/). Servier Medical Art content is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). ( https://creativecommons.org/licenses/by/4.0/). Materials and methods Animals Forty-eight adults male NMRI mice (23–27 g, 8–12 weeks old) were procured from the animal facility of Ahvaz University of Medical Sciences. The mice were housed under controlled conditions (23 ± 2 °C, 12-hour light/dark cycle) with ad libitum access to food and water. Animals were acclimatized for one week before the experiment. The working methods of animal experiments and euthanasia were approved by the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences (Ethics ID: IR.AJUMS.ABHC.REC.1402.031), and all procedures were carried out in accordance with the ARRIVE guidelines, the National Institutes of Health (NIH) standards for the care and use of laboratory animals, and relevant institutional and national regulations. Experimental design The mice were randomly divided into six groups (n = 8 per group): Control: Distilled water. Control: Distilled water. SA: Sodium arsenite (10 mg/kg). SA: Sodium arsenite (10 mg/kg). QA: Quinic acid (200 mg/kg). QA: Quinic acid (200 mg/kg). SA + QA50: SA (10 mg/kg) + QA (50 mg/kg). SA + QA50: SA (10 mg/kg) + QA (50 mg/kg). SA + QA100: SA (10 mg/kg) + QA (100 mg/kg). SA + QA100: SA (10 mg/kg) + QA (100 mg/kg). SA + QA200: SA (10 mg/kg) + QA (200 mg/kg). SA + QA200: SA (10 mg/kg) + QA (200 mg/kg). QA (Sigma-Aldrich) was dissolved in distilled water and administered via oral gavage once daily, 1 h prior to SA (Merck, Germany) exposure. Dosages were selected based on prior studies4,13,15. On day 29, fasting blood glucose (FBS) and glucose tolerance tests (GTT) were performed. On day 30, following ketamine/xylazine (100/10 mg/kg, intraperitoneally) anesthesia, blood samples were collected via cardiac puncture, and sera were separated and stored at − 80 °C until analysis (Fig. 11). The protocol for the mouse hepatotoxicity/diabetic model and treatment with quinic acid. Liver and pancreatic tissues were promptly excised. A portion of the liver and the entire pancreas were fixed in 10% phosphate-buffered formalin for histopathological analysis. An additional portion of the liver was preserved at − 80 °C for the evaluation of redox status, inflammatory markers, and protein expression via Western blot analysis. A portion of liver tissue was homogenized in radioimmunoprecipitation assay (RIPA) lysis buffer containing a protease inhibitor cocktail using a homogenizer (WiseTis HG-15D, Witeg, Germany) at 740 rpm for 2 min. The homogenates were then centrifuged, at 10,000 × g for 15 min at 4 °C, and the supernatants were collected for subsequent analyses. Protein concentration in the liver tissue supernatant was determined using the Bradford assay35. All procedures involving animal handling, treatment administration, sample collection, and data analysis were performed by investigators blinded to the group assignments to minimize observer bias. Measurement of FBS and GTT After the 4-week experimental period, mice were subjected to an overnight fast for 8–10 h before undergoing the glucose tolerance test. D-glucose (2.0 g/kg) was administered intraperitoneally. Blood samples were collected from the tail vein 0 (before) and 15, 30, 60, 90, and 120 min after the D-glucose injection. Glucose levels were determined using an ACCU-CHEK glucometer. Measurement of redox biomarkers Total thiol levels were quantified using Ellman’s reagent (5,5′-dithiobis-(2-nitrobenzoic acid) or DTNB). Briefly, 0.01 M DTNB was added to the sample supernatant and allowed to react at ambient temperature for 20 min. The development of a yellow color was monitored by measuring absorbance at 412 nm with a microplate reader, as described by Ellman (1959)36. Lipid peroxidation was evaluated through the determination of thiobarbituric acid reactive substances (TBARS). The supernatant was combined with 30% trichloroacetic acid (TCA) in phosphate buffer and centrifuged at 3500 × g for 15 min to precipitate the proteins. The resulting supernatant was transferred into microtubes containing thiobarbituric acid (TBA) reagent and incubated in a boiling water bath. The absorbance of the pink chromogen formed was recorded at 532 nm 37. The activity of SOD (ZellBio, Cat. no. ZB-SOD-96 A), and GPx (Ransel, RANDOX/RS-504) was determined according to the manufacturer’s protocols. NO levels were quantified using the Griess reagent method38. A standard curve was generated using sodium nitrite (0–100 µM), and absorbance was read at 540 nm. Nitrate was converted to nitrite using nitrate reductase prior to assay, and total NO was expressed as nmol/mg protein. To measure CAT activity, supernatants were incubated with H2O2 at room temperature. After 10 min, ammonium molybdate was added to the samples39. The absorbance at 410 nm was reported using a microplate reader (BioTek, USA). Biochemical analysis Serum concentrations of AST, ALT, ALP, TG, and total cholesterol were quantified using commercially available diagnostic kits (Pars Azmoon, Iran) via an automated biochemical analyzer. Measurement of serum levels GIP and insulin Serum GIP (Cat# SL0238Mo, SunLong Biotech co., LTD, China) and insulin (Cat# SL0293Mo, SunLong Biotech co., LTD, China) levels were measured using commercially available ELISA kits according to the manufacturer’s instructions. Measurement of TNF-α level TNF-α levels in serum were quantified using a specific ELISA kit (Cat# SL0547Mo, SunLong Biotech, China). The procedure was conducted in accordance with the manufacturer’s instructions, and absorbance was measured at 450 nm using a microplate reader. Expression of hepatic GLUT2 Liver samples were lysed and centrifuged to collect supernatants, and total protein concentration was determined. Proteins were separated by 10% SDS-PAGE and transferred to PVDF membranes. Membranes were blocked with 5% non-fat milk in PBS for 1 h at room temperature. Primary antibodies against GLUT2 (1:500, EPR16550, cat. no. ab192599; RabMAb Technology, China) and the enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (1:500, 14C10, cat. no. 2118; Cell Signaling Technology, USA) were incubated overnight at 4 °C. After washing (3 × 5 min with PBS), membranes were incubated with secondary antibodies (1:1000, Mouse anti-rabbit IgG-HRP: cat. no. sc-2357; Santa Cruz Biotechnology, Inc) for 1 h at RT. Bands were visualized using ECL reagent and quantified by densitometry using Image J v1.53. The GAPDH served as the control during Western blot analysis. Measurement of hepatic GLP-1 levels Hepatic total GLP-1 levels were measured from liver tissue homogenates using a commercially available ELISA kit (Cat# SL0234Mo) from SunLong Biotech (China) according to the manufacturer’s instructions. Histopathological analysis Following blood collection, the liver and pancreas were fixed in 10% neutral-buffered formalin. Tissues were embedded in paraffin after dehydration in graded alcohol concentrations, embedded in paraffin, and sectioned at 5 μm thickness. The sections were stained with hematoxylin and eosin (H&E) for microscopic evaluation of structural alterations. For each tissue, three slides per animal were prepared, and six randomly selected microscopic fields per slide were analyzed. A pathologist blinded to the experimental groups performed the histopathological evaluation. The diameter of the pancreatic islets of Langerhans was measured using Motic image analysis software. Statistical analysis Results are expressed as mean ± standard error of the mean (SEM) for groups consisting of eight mice. Statistical comparisons among groups were performed using one-way analysis of variance (ANOVA), followed by Tukey’s post hoc test, using GraphPad Prism software (version 9.0.0). A p-value less than or equal to 0.05 indicates statistical significance. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements This study was issued from Seyedeh Diba Aghamirzadeh’s M.Sc. thesis (TRC-0215) in toxicology and supported by the Toxicology Research Center, funded by the Vice-Chancellor of Research, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Author contributions S.D.A.: material preparation, methodology, writing original draft, and investigation. M.J.K: study conception and design, editing and revising manuscript, supervision. M.M.: writing original draft, investigation, and material preparation. A.R.: pathological analysis. M.M.: material preparation, methodology, investigation, writing original draft, editing and revising manuscript, supervision. Funding This work was supported by the Jundishapur University of Medical Sciences, Ahvaz, Iran (Grant No.: TRC-0215). Data availability No datasets were generated or analysed during the current study. Competing interests The authors declare no competing interests. Ethics approval Animal experiments, working methods, and euthanasia were performed based on animal care and use methods approved by the Ethical Committee of Ahvaz Jundishapur University of Medical Sciences (Ethics approval ID: IR.AJUMS.ABHC.REC.1402.031). Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement No datasets were generated or analysed during the current study.